Funding for this research was provided by:
Centre Hospitalier Régional Universitaire de Montpellier (UIC 9358)
Received: 23 February 2021
Accepted: 5 August 2021
First Online: 21 August 2021
: The study was approved by the ethic committee (Comité de Protection des Personnes Sud-Mediterranée III, 2014-A00500-47).
: Informed consent was obtained from all individual participants included in the study or their legally authorized representatives.
: SJ declares consulting fees from Drager, Xenios and Fisher & Paykel. BJ does not declare any conflicts of interests. GC declares speaker fees from Aspen medical and Orion pharma and consulting fees from Orion pharma. JFT declares speaker fees from Merck, Pfizer, Biomerieux; consulting fees from Pfizer, Gilead, Merck, Nabriva, Paratek, Medimune and research grants from 3M, Merck, Pfizer. Other authors do not declare any conflicts of interests.